BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 2021;19:103-16. [PMID: 33358151 DOI: 10.1016/j.clgc.2020.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Labaki C, Choueiri TK. Perioperative immunotherapy for renal cell carcinoma: looking beyond the data. Nat Rev Clin Oncol 2022. [DOI: 10.1038/s41571-022-00710-5] [Reference Citation Analysis]
2 Msaouel P. Less is More? First Impressions from COSMIC-313. Cancer Invest 2022;:1-12. [PMID: 36239611 DOI: 10.1080/07357907.2022.2136681] [Reference Citation Analysis]
3 Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel) 2022;14:3923. [PMID: 36010916 DOI: 10.3390/cancers14163923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bigot C, Boudier P, Ladoire S, Barthélémy P. Advanced nccRCC: what therapeutic options in 2022? Bulletin du Cancer 2022;109:2S39-2S46. [DOI: 10.1016/s0007-4551(22)00237-5] [Reference Citation Analysis]
5 Fontes-Sousa M, Magalhães H, Oliveira A, Carneiro F, Dos Reis FP, Madeira PS, Meireles S. Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? Adv Ther 2022;39:1107-25. [PMID: 35025061 DOI: 10.1007/s12325-021-02007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treatment and Research Communications 2022;33:100640. [DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
7 Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021;6:100304. [PMID: 34864348 DOI: 10.1016/j.esmoop.2021.100304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 2021;13:6022. [PMID: 34885132 DOI: 10.3390/cancers13236022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pezzicoli G, Filoni E, Gernone A, Cosmai L, Rizzo M, Porta C. Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors. Cancer Manag Res 2021;13:7623-36. [PMID: 34675658 DOI: 10.2147/CMAR.S267220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tung I, Sahu A. Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Front Oncol 2021;11:707214. [PMID: 34527581 DOI: 10.3389/fonc.2021.707214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
11 Hsieh JJ. The 2021 Variant Histology Issue. Clin Genitourin Cancer 2021;19:93-4. [PMID: 34088495 DOI: 10.1016/j.clgc.2021.02.006] [Reference Citation Analysis]
12 Zarrabi K, Walzer E, Zibelman M. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers (Basel) 2021;13:3652. [PMID: 34359554 DOI: 10.3390/cancers13153652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Geynisman DM, Plimack ER. Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress. Eur Urol 2021;80:171-3. [PMID: 33972094 DOI: 10.1016/j.eururo.2021.04.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 2021;13:2170. [PMID: 33946504 DOI: 10.3390/cancers13092170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Wang XM, Zhang Y, Mannan R, Skala SL, Rangaswamy R, Chinnaiyan A, Su F, Cao X, Zelenka-Wang S, McMurry L, Xiao H, Spratt DE, Sangoi AR, Shao L, Betz BL, Brown N, Tickoo SK, McKenney JK, Argani P, Gupta S, Reuter VE, Chinnaiyan AM, Dhanasekaran SM, Mehra R. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Mod Pathol 2021;34:1596-607. [PMID: 33854184 DOI: 10.1038/s41379-021-00803-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
16 Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treat Res Commun 2021;27:100349. [PMID: 33725559 DOI: 10.1016/j.ctarc.2021.100349] [Reference Citation Analysis]
17 Borchiellini D, Barthélémy P. Cabozantinib: a new first-line option for papillary renal cell carcinoma? Lancet 2021;397:645-7. [PMID: 33592177 DOI: 10.1016/S0140-6736(21)00316-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]